Company Details
  • Taizhou Volsen Chemical Co., Ltd.

  •  [Zhejiang,China]
  • Business Type:Manufacturer
  • Main Mark: Americas , Asia , East Europe , Europe , North Europe , Other Markets , West Europe , Worldwide
  • Exporter:91% - 100%
  • Certs:GS, CE, ISO9001, ISO14000
  • Description:Hign Purity Tivozanib 475108-18-0,Cancer Treatment Tivozanib 475108-18-0,Cas Number 475108-18-0
Taizhou Volsen Chemical Co., Ltd. Hign Purity Tivozanib 475108-18-0,Cancer Treatment Tivozanib 475108-18-0,Cas Number 475108-18-0
Home > Products > Active Pharmaceutical Ingredients > VEGFR Inhibitor Tivozanib(AV-951,KRN951) CAS 475108-18-0

VEGFR Inhibitor Tivozanib(AV-951,KRN951) CAS 475108-18-0

Share to:  
    Unit Price: USD 100 / Kilogram
    Payment Type: L/C,T/T
    Incoterm: CIF
    Min. Order: 1 Kilogram
    Delivery Time: 3 Days

Basic Info

Model No.:  475108-18-0

Additional Info

Packaging: 25KGS/DRUM

Productivity: 30T/Y


Transportation: Ocean,Land,Air

Place of Origin: CHINA

Supply Ability: 30T/Y

Certificate: YES

Product Description

Tivozanib(AV-951) cas number 475108-18-0 is an anti-tumor targeted therapy, a multi-target anti-angiogenesis inhibitor,as anti-cancer new drug, mainly used for the treatment of renal cancer, showing good curative effect in the first-line treatment of advanced renal cell carcinoma. The main target is vascular endothelial growth factor VEGFR 1, 2, 3, which acts to treat kidney tumor cells by inhibiting these three vascular endothelial growth factor receptors. The average survival time after taking tivozanib is 11.8 months. There was no deterioration in the month, and the effect of the patients with advanced kidney cancer who had undergone surgical removal of some kidneys could reach nearly 14.8 months. Phase III clinical trials of the drug confirmed that the average disease-free survival of the tivozanib-treated group was significantly better than the sorafenib control group regardless of whether the patient had previously received systematic anti-tumor therapy. Therefore, the market potential of Tivozanib is very broad. According to a drug expert's assessment, the drug may become a blockbuster drug after its market launch.
In vivo studies have shown that tivozanib cas number 475108-18-0 can reduce the microvessel density of transplanted tumors and inhibit the level of VEGFR-2 phosphorylation in transplanted tumors, especially when the oral tivozanib concentration reaches 1 mg/kg. In the athymic mice, tivozanib almost inhibited the growth of all transplanted tumors, and the tumor growth inhibition rate (TGI) was >85%. Tivozanib acts on human xenograft models including the lung, thymus, colon, ovary, pancreas and prostate. A study of a murine peritoneal disseminated tumor model showed that tivozanib prolonged the lifespan of tumor-bearing mice.

Thera. Category:Anti-tumor

Cas No.: 475108-18-0


Molecular Formula:C22H19ClN4O5


Molecular Weight:454.86

Pharmacopeia: in house spe.

Specifications:Available on request

Packing:Export worthy packing

Material Safety Data Sheet:Available on request

Looking for ideal Hign Purity Tivozanib 475108-18-0 Manufacturer & supplier ? We have a wide selection at great prices to help you get creative. All the Cancer Treatment Tivozanib 475108-18-0 are quality guaranteed. We are China Origin Factory of Cas Number 475108-18-0. If you have any question, please feel free to contact us.

Product Categories : Active Pharmaceutical Ingredients

Product Images
  • VEGFR Inhibitor Tivozanib(AV-951,KRN951) CAS 475108-18-0
Email to this supplier
  • *Subject:
  • *Messages:
    Your message must be between 20-8000 characters
Copyright © 2019 Taizhou Volsen Chemical Co., Ltd. All rights reserved.
Communicate with Supplier?Supplier
Amy Cheng Ms. Amy Cheng
What can I do for you?